{
    "root": "23ba06a5-8314-49cf-b9de-fa3caad1a17a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "NEOSTIGMINE METHYLSULFATE"
    },
    "value": "20250318",
    "ingredients": [
        {
            "name": "NEOSTIGMINE METHYLSULFATE",
            "code": "98IMH7M386"
        },
        {
            "name": "PHENOL",
            "code": "339NCG44TV"
        },
        {
            "name": "SODIUM ACETATE",
            "code": "4550K0SC9B"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "indications": "Neostigmine methylsulfate injection is a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery.",
    "contraindications": "Should be administered by trained healthcare providers ( 2.1 ) Peripheral nerve stimulator and monitoring for twitch responses should be used to determine when neostigmine methylsulfate injection should be initiated and if additional doses are needed ( 2.2 ) − For reversal of NMBAs with shorter half-lives, when first twitch response is substantially greater than 10% of baseline, or when a second twitch is present: 0.03 mg/kg by intravenous route ( 2.2 ) − For reversal of NMBAs with longer half-lives or when first twitch response is close to 10% of baseline: 0.07 mg/kg by intravenous route ( 2.2 ) Maximum total dosage is 0.07 mg/kg or up to a total of 5 mg (whichever is less) ( 2.2 ) An anticholinergic agent, e.g., atropine sulfate or glycopyrrolate, should be administered prior to or concomitantly with neostigmine methylsulfate injection ( 2.4 )",
    "warningsAndPrecautions": "Neostigmine Methylsulfate Injection, USP is clear, colorless solution, free from visible particulate matter intended for intravenous use. It is available as follows: \n                  \n                  \n                     \n                        \n                        \n                        \n                     \n                     \n                        \n                            NDC No.\n                               \n                            Strength\n                               \n                            Vial Size\n                               \n                        \n                        \n                            14445-413-01 \n                            5 mg/10 mL (0.5 mg/mL) \n                            10 mL multiple-dose vials (supplied in packages of 10) \n                        \n                        \n                            14445-414-01 \n                            10 mg/10 mL (1 mg/mL) \n                            10 mL multiple-dose vials (supplied in packages of 10) \n                        \n                     \n                  \n                  \n                  The vial stopper is not made with natural rubber latex.\n                  \n                  Neostigmine Methylsulfate Injection USP should be stored at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (see USP Controlled Room Temperature). Protect from light. Store in carton until time of use.\n                  \n                  KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.\n                  \n                  Manufactured By:\n                     Indoco Remedies Limited\n                      Verna, Goa 403722, INDIA Code: No.: GO/DRUGS/557\n                  \n                  Rev : 03/2025",
    "adverseReactions": "Neostigmine methylsulfate injection is contraindicated in patients with:\n                  \n                     known hypersensitivity to neostigmine methylsulfate (known hypersensitivity reactions have included urticaria, angioedema, erythema multiforme, generalized rash, facial swelling, peripheral edema, pyrexia, flushing, hypotension, bronchospasm, bradycardia and anaphylaxis).\n                  \n                  \n                     peritonitis or mechanical obstruction of the intestinal or urinary tract."
}